These findings are consistent with previous reports in malignancies (28, 29), pulmonary fibrosis (30), and inflammatory bowel disease (31), suggesting that CHI3L1 may serve as a potential common molecular biomarker in inflammation-associated pathologies. Here, CHI3L1 is linked to pulmonary fibrosis.